The Future of Subcutaneous Implantable Cardiovertodefibrilators

Carle Hone: The technology and procedure that is presented today in JAG may be an important advance in this field. We are talking about patients with congenital heart disease. In a French study of the total number of patients who receive subcutaneous implantable cardiovertodefibrilator, 2% had Congenital Heart Disease. Almost half of these patients withCongenitalHeartDisease had tatrazia follow, univentricular heart; extra transposition of great arteries.